



Sen. Julie A. Morrison

Filed: 3/17/2023

10300SB1987sam001

LRB103 25792 RLC 58970 a

1 AMENDMENT TO SENATE BILL 1987

2 AMENDMENT NO. _____. Amend Senate Bill 1987 by replacing
3 everything after the enacting clause with the following:

4 "Section 5. The Illinois Controlled Substances Act is
5 amended by changing Section 204 as follows:

6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

7 Sec. 204. (a) The controlled substances listed in this
8 Section are included in Schedule I.

9 (b) Unless specifically excepted or unless listed in
10 another schedule, any of the following opiates, including
11 their isomers, esters, ethers, salts, and salts of isomers,
12 esters, and ethers, whenever the existence of such isomers,
13 esters, ethers and salts is possible within the specific
14 chemical designation:

15 (1) Acetylmethadol;

16 (1.1) Acetyl-alpha-methylfentanyl

1 (N-[1-(1-methyl-2-phenethyl)-
2 4-piperidinyl]-N-phenylacetamide);
3 (2) Allylprodine;
4 (3) Alphacetylmethadol, except
5 levo-alphacetylmethadol (also known as levo-alpha-
6 acetylmethadol, levomethadyl acetate, or LAAM);
7 (4) Alphameprodine;
8 (5) Alphamethadol;
9 (6) Alpha-methylfentanyl
10 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
11 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
12 propanilido) piperidine;
13 (6.1) Alpha-methylthiofentanyl
14 (N-[1-methyl-2-(2-thienyl)ethyl-
15 4-piperidinyl]-N-phenylpropanamide);
16 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
17 (7.1) PEPAP
18 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
19 (8) Benzethidine;
20 (9) Betacetylmethadol;
21 (9.1) Beta-hydroxyfentanyl
22 (N-[1-(2-hydroxy-2-phenethyl)-
23 4-piperidinyl]-N-phenylpropanamide);
24 (10) Betameprodine;
25 (11) Betamethadol;
26 (12) Betaprodine;

- 1 (13) Clonitazene;
- 2 (14) Dextromoramide;
- 3 (15) Diampromide;
- 4 (16) Diethylthiambutene;
- 5 (17) Difenoquin;
- 6 (18) Dimenoxadol;
- 7 (19) Dimepseptanol;
- 8 (20) Dimethylthiambutene;
- 9 (21) Dioxaphetylbutyrate;
- 10 (22) Dipipanone;
- 11 (23) Ethylmethylthiambutene;
- 12 (24) Etonitazene;
- 13 (25) Etoxadine;
- 14 (26) Furethidine;
- 15 (27) Hydroxypethidine;
- 16 (28) Ketobemidone;
- 17 (29) Levomoramide;
- 18 (30) Levophenacymorphan;
- 19 (31) 3-Methylfentanyl
20 (N-[3-methyl-1-(2-phenylethyl)-
21 4-piperidyl]-N-phenylpropanamide);
- 22 (31.1) 3-Methylthiofentanyl
23 (N-[(3-methyl-1-(2-thienyl)ethyl-
24 4-piperidinyl]-N-phenylpropanamide);
- 25 (32) Morpheridine;
- 26 (33) Noracymethadol;

- 1 (34) Norlevorphanol;
- 2 (35) Normethadone;
- 3 (36) Norpipanone;
- 4 (36.1) Para-fluorofentanyl
- 5 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
- 6 4-piperidinyl]propanamide);
- 7 (37) Phenadoxone;
- 8 (38) Phenampromide;
- 9 (39) Phenomorphan;
- 10 (40) Phenoperidine;
- 11 (41) Piritramide;
- 12 (42) Proheptazine;
- 13 (43) Properidine;
- 14 (44) Propiram;
- 15 (45) Racemoramide;
- 16 (45.1) Thiofentanyl
- 17 (N-phenyl-N-[1-(2-thienyl)ethyl-
- 18 4-piperidinyl]-propanamide);
- 19 (46) Tilidine;
- 20 (47) Trimeperidine;
- 21 (48) Beta-hydroxy-3-methylfentanyl (other name:
- 22 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
- 23 N-phenylpropanamide);
- 24 (49) Furanyl fentanyl (FU-F);
- 25 (50) Butyryl fentanyl;
- 26 (51) Valeryl fentanyl;

1 (52) Acetyl fentanyl;

2 (53) Beta-hydroxy-thiofentanyl;

3 (54) 3,4-dichloro-N-[2-

4 (dimethylamino)cyclohexyl]-N-

5 methylbenzamide (U-47700);

6 (55) 4-chloro-N-[1-[2-

7 (4-nitrophenyl)ethyl]-2-piperidinylidene]-

8 benzenesulfonamide (W-18);

9 (56) 4-chloro-N-[1-(2-phenylethyl)

10 -2-piperidinylidene]-benzenesulfonamide (W-15);

11 (57) acrylfentanyl (acryloylfentanyl).

12 (c) Unless specifically excepted or unless listed in
13 another schedule, any of the following opium derivatives, its
14 salts, isomers and salts of isomers, whenever the existence of
15 such salts, isomers and salts of isomers is possible within
16 the specific chemical designation:

17 (1) Acetorphine;

18 (2) Acetyldihydrocodeine;

19 (3) Benzylmorphine;

20 (4) Codeine methylbromide;

21 (5) Codeine-N-Oxide;

22 (6) Cyprenorphine;

23 (7) Desomorphine;

24 (8) Diacetyldihydromorphine (Dihydroheroin);

25 (9) Dihydromorphine;

26 (10) Drotebanol;

- 1 (11) Etorphine (except hydrochloride salt);
- 2 (12) Heroin;
- 3 (13) Hydromorphenol;
- 4 (14) Methyldesorphine;
- 5 (15) Methyldihydromorphine;
- 6 (16) Morphine methylbromide;
- 7 (17) Morphine methylsulfonate;
- 8 (18) Morphine-N-Oxide;
- 9 (19) Myrophine;
- 10 (20) Nicocodeine;
- 11 (21) Nicomorphine;
- 12 (22) Normorphine;
- 13 (23) Pholcodine;
- 14 (24) Thebacon.

15 (d) Unless specifically excepted or unless listed in
16 another schedule, any material, compound, mixture, or
17 preparation which contains any quantity of the following
18 hallucinogenic substances, or which contains any of its salts,
19 isomers and salts of isomers, whenever the existence of such
20 salts, isomers, and salts of isomers is possible within the
21 specific chemical designation (for the purposes of this
22 paragraph only, the term "isomer" includes the optical,
23 position and geometric isomers):

- 24 (1) 3,4-methylenedioxyamphetamine
25 (alpha-methyl, 3,4-methylenedioxyphenethylamine,
26 methylenedioxyamphetamine, MDA);

- 1 (1.1) Alpha-ethyltryptamine
2 (some trade or other names: etryptamine;
3 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
4 3-(2-aminobutyl)indole; a-ET; and AET);
5 (2) 3,4-methylenedioxymethamphetamine (MDMA);
6 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
7 (also known as: N-ethyl-alpha-methyl-
8 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
9 and MDEA);
10 (2.2) N-Benzylpiperazine (BZP);
11 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
12 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
13 (4) 3,4,5-trimethoxyamphetamine (TMA);
14 (5) (Blank);
15 (6) Diethyltryptamine (DET);
16 (7) Dimethyltryptamine (DMT);
17 (7.1) 5-Methoxy-diallyltryptamine;
18 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
19 (9) Ibogaine (some trade and other names:
20 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
21 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
22 indole; Tabernanthe iboga);
23 (10) Lysergic acid diethylamide;
24 (10.1) Salvinorin A;
25 (10.5) Salvia divinorum (meaning all parts of the
26 plant presently classified botanically as Salvia

1 divinorum, whether growing or not, the seeds thereof, any
2 extract from any part of that plant, and every compound,
3 manufacture, salts, isomers, and salts of isomers whenever
4 the existence of such salts, isomers, and salts of isomers
5 is possible within the specific chemical designation,
6 derivative, mixture, or preparation of that plant, its
7 seeds or extracts);

8 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

9 (12) Peyote (meaning all parts of the plant presently
10 classified botanically as *Lophophora williamsii* Lemaire,
11 whether growing or not, the seeds thereof, any extract
12 from any part of that plant, and every compound,
13 manufacture, salts, derivative, mixture, or preparation of
14 that plant, its seeds or extracts);

15 (13) N-ethyl-3-piperidyl benzilate (JB 318);

16 (14) N-methyl-3-piperidyl benzilate;

17 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
18 (also known as N-hydroxy-alpha-methyl-
19 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

20 (15) Parahexyl; some trade or other names:
21 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
22 dibenzo (b,d) pyran; Synhexyl;

23 (16) Psilocybin;

24 (17) Psilocyn;

25 (18) Alpha-methyltryptamine (AMT);

26 (19) 2,5-dimethoxyamphetamine

1 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

2 (20) 4-bromo-2,5-dimethoxyamphetamine

3 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

4 4-bromo-2,5-DMA);

5 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

6 Some trade or other names: 2-(4-bromo-

7 2,5-dimethoxyphenyl)-1-aminoethane;

8 alpha-desmethyl DOB, 2CB, Nexus;

9 (21) 4-methoxyamphetamine

10 (4-methoxy-alpha-methylphenethylamine;

11 paramethoxyamphetamine; PMA);

12 (22) (Blank);

13 (23) Ethylamine analog of phencyclidine.

14 Some trade or other names:

15 N-ethyl-1-phenylcyclohexylamine,

16 (1-phenylcyclohexyl) ethylamine,

17 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

18 (24) Pyrrolidine analog of phencyclidine. Some trade

19 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,

20 PHP;

21 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

22 (26) 2,5-dimethoxy-4-ethylamphetamine

23 (another name: DOET);

24 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

25 (another name: TCPy);

26 (28) (Blank);

1 (29) Thiophene analog of phencyclidine (some trade
2 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
3 2-thienyl analog of phencyclidine; TCP; TCP);

4 (29.1) Benzothiophene analog of phencyclidine. Some
5 trade or other names: BTCP or benocyclidine;

6 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

7 (30) Bufotenine (some trade or other names:
8 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
9 3-(2-dimethylaminoethyl)-5-indolol;
10 5-hydroxy-N,N-dimethyltryptamine;
11 N,N-dimethylserotonin; mappine);

12 (31) (Blank);

13 (32) (Blank);

14 (33) (Blank);

15 (34) (Blank);

16 (34.5) (Blank);

17 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
18 (2-methyloctan-2-yl)-6a,7,
19 10,10a-tetrahydrobenzo[c]chromen-1-ol
20 Some trade or other names: HU-210;

21 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
22 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
23 tetrahydrobenzo[c]chromen-1-ol, its isomers,
24 salts, and salts of isomers; Some trade or other
25 names: HU-210, Dexanabinol;

26 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-

1 6,6-dimethyl-3-(2-methyloctan-2-yl)-
2 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

3 Some trade or other names: HU-211;

4 (37) (Blank);

5 (38) (Blank);

6 (39) (Blank);

7 (40) (Blank);

8 (41) (Blank);

9 (42) Any compound structurally derived from
10 3-(1-naphthoyl)indole or
11 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
12 nitrogen atom of the indole ring by alkyl, haloalkyl,
13 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
14 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl whether or not further substituted
16 in the indole ring to any extent, whether or not
17 substituted in the naphthyl ring to any extent. Examples
18 of this structural class include, but are not limited to,
19 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

20 (43) Any compound structurally derived from
21 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
22 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24 halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 in the pyrrole ring to any extent, whether or not

1 substituted in the naphthyl ring to any extent. Examples
2 of this structural class include, but are not limited to,
3 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

4 (44) Any compound structurally derived from
5 1-(1-naphthylmethyl)indene by substitution at the
6 3-position of the indene ring by alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl whether or not further substituted
10 in the indene ring to any extent, whether or not
11 substituted in the naphthyl ring to any extent. Examples
12 of this structural class include, but are not limited to,
13 JWH-176;

14 (45) Any compound structurally derived from
15 3-phenylacetylindole by substitution at the nitrogen atom
16 of the indole ring with alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further substituted
20 in the indole ring to any extent, whether or not
21 substituted in the phenyl ring to any extent. Examples of
22 this structural class include, but are not limited to,
23 JWH-167, JWH-250, JWH-251, and RCS-8;

24 (46) Any compound structurally derived from
25 2-(3-hydroxycyclohexyl)phenol by substitution at the
26 5-position of the phenolic ring by alkyl, haloalkyl,

1 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
2 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl, whether or not substituted in the
4 cyclohexyl ring to any extent. Examples of this structural
5 class include, but are not limited to, CP 47, 497 and its
6 C8 homologue (cannabicyclohexanol);

7 (46.1) Any compound structurally derived from
8 3-(benzoyl) indole with substitution at the nitrogen atom
9 of the indole ring by an alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl group whether or not further
13 substituted in the indole ring to any extent and whether
14 or not substituted in the phenyl ring to any extent.
15 Examples of this structural class include, but are not
16 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
17 48,098), and RCS-4;

18 (47) (Blank);

19 (48) (Blank);

20 (49) (Blank);

21 (50) (Blank);

22 (51) (Blank);

23 (52) (Blank);

24 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.

25 Some trade or other names: 2C-T-7;

26 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some

1 trade or other names: 2C-E;

2 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some

3 trade or other names: 2C-D;

4 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some

5 trade or other names: 2C-C;

6 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
7 or other names: 2C-I;

8 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
9 trade or other names: 2C-T-2;

10 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
11 Some trade or other names: 2C-T-4;

12 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
13 other names: 2C-H;

14 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
15 trade or other names: 2C-N;

16 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
17 trade or other names: 2C-P;

18 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
19 Some trade or other names: 2C-G;

20 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
21 phenethylamine referred to in subparagraphs (20.1), (53),
22 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
23 (53.8), (53.9), and (53.10) including, but not limited to,
24 25I-NBOMe and 25C-NBOMe;

25 (54) 5-Methoxy-N,N-diisopropyltryptamine;

26 (55) (Blank);

1 (56) (Blank);

2 (57) (Blank);

3 (58) (Blank);

4 (59) 3-cyclopropoylindole with substitution at the
5 nitrogen atom of the indole ring by alkyl, haloalkyl,
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indole ring to any extent, whether or not
10 substituted on the cyclopropyl ring to any extent:
11 including, but not limited to, XLR11, UR144, FUB-144;

12 (60) 3-adamantoylindole with substitution at the
13 nitrogen atom of the indole ring by alkyl, haloalkyl,
14 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
15 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not further substituted
17 on the indole ring to any extent, whether or not
18 substituted on the adamantyl ring to any extent:
19 including, but not limited to, AB-001;

20 (61) N-(adamantyl)-indole-3-carboxamide with
21 substitution at the nitrogen atom of the indole ring by
22 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
23 cycloalkylethyl, aryl halide, alkyl aryl halide,
24 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 on the indole ring to any extent, whether or not

1 substituted on the adamantyl ring to any extent:
2 including, but not limited to, APICA/2NE-1, STS-135;

3 (62) N-(adamantyl)-indazole-3-carboxamide with
4 substitution at a nitrogen atom of the indazole ring by
5 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
6 cycloalkylethyl, aryl halide, alkyl aryl halide,
7 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indazole ring to any extent, whether or not
10 substituted on the adamantyl ring to any extent:
11 including, but not limited to, AKB48, 5F-AKB48;

12 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
13 with substitution at the nitrogen atom of the indole ring
14 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15 cycloalkylethyl, aryl halide, alkyl aryl halide,
16 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indole ring to any extent, whether or not
19 substituted on the quinoline ring to any extent:
20 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;

21 (64) 3-(1-naphthoyl)indazole with substitution at the
22 nitrogen atom of the indazole ring by alkyl, haloalkyl,
23 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
24 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 on the indazole ring to any extent, whether or not

1 substituted on the naphthyl ring to any extent: including,
2 but not limited to, THJ-018, THJ-2201;

3 (65) 2-(1-naphthoyl)benzimidazole with substitution
4 at the nitrogen atom of the benzimidazole ring by alkyl,
5 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
6 aryl halide, alkyl aryl halide,
7 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the benzimidazole ring to any extent, whether or not
10 substituted on the naphthyl ring to any extent: including,
11 but not limited to, FUBIMINA;

12 (66)
13 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
14 3-carboxamide with substitution on the nitrogen atom of
15 the indazole ring by alkyl, haloalkyl, alkenyl,
16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17 halide, 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 on the indazole ring to any extent: including, but not
20 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

21 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
22 indazole-3-carboxamide with substitution on the nitrogen
23 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
24 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
25 halide, 1-(N-methyl-2-piperidinyl)methyl, or
26 2-(4-morpholinyl)ethyl, whether or not further substituted

1 on the indazole ring to any extent: including, but not
2 limited to, ADB-PINACA, ADB-FUBINACA;

3 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
4 indole-3-carboxamide with substitution on the nitrogen
5 atom of the indole ring by alkyl, haloalkyl, alkenyl,
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
7 halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl, whether or not further substituted
9 on the indole ring to any extent: including, but not
10 limited to, ADBICA, 5F-ADBICA;

11 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
12 3-carboxamide with substitution on the nitrogen atom of
13 the indole ring by alkyl, haloalkyl, alkenyl,
14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
15 halide, 1-(N-methyl-2-piperidinyl)methyl, or
16 2-(4-morpholinyl)ethyl, whether or not further substituted
17 on the indole ring to any extent: including, but not
18 limited to, ABICA, 5F-ABICA;

19 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
20 methylbutanoate with substitution on the nitrogen atom of
21 the indazole ring by alkyl, haloalkyl, alkenyl,
22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
23 halide, 1-(N-methyl-2-piperidinyl)methyl, or
24 2-(4-morpholinyl)ethyl, whether or not further substituted
25 on the indazole ring to any extent: including, but not
26 limited to, AMB, 5F-AMB;

1 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
2 dimethylbutanoate with substitution on the nitrogen atom
3 of the indazole ring by alkyl, haloalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
5 halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the indazole ring to any extent: including, but not
8 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

9 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
10 methylbutanoate with substitution on the nitrogen atom of
11 the indole ring by alkyl, haloalkyl, alkenyl,
12 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
13 halide, 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl, whether or not further substituted
15 on the indazole ring to any extent: including, but not
16 limited to, MMB018, MMB2201, and AMB-CHMICA;

17 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
18 dimethylbutanoate with substitution on the nitrogen atom
19 of the indole ring by alkyl, haloalkyl, alkenyl,
20 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
21 halide, 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not further substituted
23 on the indazole ring to any extent: including, but not
24 limited to, MDMB-CHMICA;

25 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
26 indazole-3-carboxamide with substitution on the nitrogen

1 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
3 halide, 1-(N-methyl-2-piperidinyl)methyl, or
4 2-(4-morpholinyl)ethyl, whether or not further substituted
5 on the indazole ring to any extent: including, but not
6 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

7 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
8 3-carboxamide with substitution on the nitrogen atom of
9 the indole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further substituted
13 on the indazole ring to any extent: including, but not
14 limited to, APP-PICA and 5-fluoro-APP-PICA;

15 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
16 4-AcO-DMT;

17 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
18 name 5-MeO-MIPT;

19 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

20 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

21 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

22 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
23 (4-HO-MiPT);

24 (82) Fluorophenylpiperazine;

25 (83) Methoxetamine;

26 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-

1 ethcathinone).

2 (e) Unless specifically excepted or unless listed in
3 another schedule, any material, compound, mixture, or
4 preparation which contains any quantity of the following
5 substances having a depressant effect on the central nervous
6 system, including its salts, isomers, and salts of isomers
7 whenever the existence of such salts, isomers, and salts of
8 isomers is possible within the specific chemical designation:

9 (1) mecloqualone;

10 (2) methaqualone; and

11 (3) gamma hydroxybutyric acid.

12 (f) Unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or
14 preparation which contains any quantity of the following
15 substances having a stimulant effect on the central nervous
16 system, including its salts, isomers, and salts of isomers:

17 (1) Fenethylline;

18 (2) N-ethylamphetamine;

19 (3) Aminorex (some other names:

20 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

21 4-5-dihydro-5-phenyl-2-oxazolamine) and its

22 salts, optical isomers, and salts of optical isomers;

23 (4) Methcathinone (some other names:

24 2-methylamino-1-phenylpropan-1-one;

25 Ephedrone; 2-(methylamino)-propiofenone;

26 alpha-(methylamino)propiofenone; N-methylcathinone;

1 methycathinone; Monomethylpropion; UR 1431) and its
2 salts, optical isomers, and salts of optical isomers;

3 (5) Cathinone (some trade or other names:
4 2-aminopropiophenone; alpha-aminopropiophenone;
5 2-amino-1-phenyl-propanone; norephedrone);

6 (6) N,N-dimethylamphetamine (also known as:
7 N,N-alpha-trimethyl-benzeneethanamine;
8 N,N-alpha-trimethylphenethylamine);

9 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
10 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

11 (8) 3,4-Methylenedioxypropylamphetamine (MDPV);

12 (9) Halogenated amphetamines and
13 methamphetamines - any compound derived from either
14 amphetamine or methamphetamine through the substitution
15 of a halogen on the phenyl ring, including, but not
16 limited to, 2-fluoroamphetamine, 3-
17 fluoroamphetamine and 4-fluoroamphetamine;

18 (10) Aminopropylbenzofuran (APB):
19 including 4-(2-Aminopropyl) benzofuran, 5-
20 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
21 benzofuran, and 7-(2-Aminopropyl) benzofuran;

22 (11) Aminopropyldihydrobenzofuran (APDB):
23 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
24 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
25 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
26 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

1 (12) Methylaminopropylbenzofuran
2 (MAPB): including 4-(2-methylaminopropyl)
3 benzofuran, 5-(2-methylaminopropyl)benzofuran,
4 6-(2-methylaminopropyl)benzofuran
5 and 7-(2-methylaminopropyl)benzofuran.

6 (g) Temporary listing of substances subject to emergency
7 scheduling. Any material, compound, mixture, or preparation
8 that contains any quantity of the following substances:

9 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
10 (benzylfentanyl), its optical isomers, isomers, salts, and
11 salts of isomers;

12 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
13 phenylpropanamide (thenylfentanyl), its optical isomers,
14 salts, and salts of isomers.

15 (h) Synthetic cathinones. Unless specifically excepted,
16 any chemical compound which is not approved by the United
17 States Food and Drug Administration or, if approved, is not
18 dispensed or possessed in accordance with State or federal
19 law, not including bupropion, structurally derived from
20 2-aminopropan-1-one by substitution at the 1-position with
21 either phenyl, naphthyl, or thiophene ring systems, whether or
22 not the compound is further modified in one or more of the
23 following ways:

24 (1) by substitution in the ring system to any extent
25 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
26 halide substituents, whether or not further substituted in

1 the ring system by one or more other univalent
2 substituents. Examples of this class include, but are not
3 limited to, 3,4-Methylenedioxcathinone (bk-MDA);

4 (2) by substitution at the 3-position with an acyclic
5 alkyl substituent. Examples of this class include, but are
6 not limited to, 2-methylamino-1-phenylbutan-1-one
7 (buphedrone); or

8 (3) by substitution at the 2-amino nitrogen atom with
9 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
10 inclusion of the 2-amino nitrogen atom in a cyclic
11 structure. Examples of this class include, but are not
12 limited to, Dimethylcathinone, Ethcathinone, and
13 α -Pyrrolidinopropiophenone (α -PPP); or

14 Any other synthetic cathinone which is not approved by the
15 United States Food and Drug Administration or, if approved, is
16 not dispensed or possessed in accordance with State or federal
17 law.

18 (i) Synthetic cannabinoids or piperazines. Any synthetic
19 cannabinoid or piperazine which is not approved by the United
20 States Food and Drug Administration or, if approved, which is
21 not dispensed or possessed in accordance with State and
22 federal law.

23 (j) Unless specifically excepted or listed in another
24 schedule, any chemical compound which is not approved by the
25 United States Food and Drug Administration or, if approved, is
26 not dispensed or possessed in accordance with State or federal

1 law, and is derived from the following structural classes and
2 their salts:

3 (1) Benzodiazepine class: A fused 1,4-diazepine and
4 benzene ring structure with a phenyl connected to the
5 1,4-diazepine ring, with any substitution(s) or
6 replacement(s) on the 1,4-diazepine or benzene ring, any
7 substitution(s) on the phenyl ring, or any combination
8 thereof. Examples of this class include but are not
9 limited to: Clonazolam, Flualprazolam; or

10 (2) Thienodiazepine class: A fused 1,4-diazepine and
11 thiophene ring structure with a phenyl connected to the
12 1,4-diazepine ring, with any substitution(s) or
13 replacement(s) on the 1,4-diazepine or thiophene ring, any
14 substitution(s) on the phenyl ring, or any combination
15 thereof. Examples of this class include but are not
16 limited to: Etizolam.

17 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
18 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
19 8-14-18.)".